Large Pipeline The first-quarter figures were sobering. BioNTech generated revenue of just EUR 118.1 million, a decline of ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

German vaccine manufacturer BioNTech, which rose to global prominence with its Covid-19 vaccine developed alongside Pfizer, plans to close several production sites, with up to 1,860 jobs affected. The ...

Fintel reports that on May 27, 2026, UBS upgraded their outlook for BioNTech SE - Depositary Receipt (NasdaqGS:BNTX) from ...

As Summit Therapeutics’ Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.

Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds An update from ...

In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard ...

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 ...

The beauty of mRNA vaccines is their ability to be quickly updated. Though the vaccine makers are confident in their original vaccines, as COVID-19 continues to change, the vaccines can change, too.

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. BioNTech said Thursday it would buy ...

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...